Literature DB >> 19264832

Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?

E Vasile, C Tibaldi, A Falcone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19264832     DOI： 10.1093/annonc/mdp013

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

Review 1.  Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.

Authors:  Tony S K Mok; Manolo D'arcangelo; Raffaele Califano
Journal:  Drugs       Date:  2012-06-19       Impact factor: 9.546

2.  First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.

Authors:  Kim-Son H Nguyen; Joel W Neal
Journal:  Biologics       Date:  2012-09-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.